Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 15, 2008. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific equity transaction.
- Transaction Price: $35.41 per American Depositary Receipt (ADR).
- Transaction Type: Increase in interest via dividend re-investment.
- Dividend Payment Date: October 9, 2008.
Material Changes
The filing reports an increase in the shareholding interest of Mr. D J Phelan. This change resulted from the automatic re-investment of dividends paid to shareholders on October 9, 2008, rather than a direct market purchase or sale.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on business strategy, risks, contingencies, or unusual items. The document is a regulatory disclosure of a specific director transaction under Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Verify the total number of ADRs held by Mr. D J Phelan following the October 14, 2008 notification.
- Confirm the dividend amount per share paid on October 9, 2008, to validate the re-investment calculation.
- Check subsequent filings for any further changes in director holdings or related party transactions.